• 1
    Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin. 1995;48:629.
  • 2
    Woolf SH. Screening for prostate cancer with prostate-specific antigen. N Engl J Med. 1995;333:14015.
  • 3
    Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med. 1993;153:252937.
  • 4
    Perkins T. Concern grows over prostate cancer treatment options. JNCI. 1994;86:9878.
  • 5
    Menon M, Parulker BG, Baker S. Should we treat localized prostate cancer. An opinion. Urology. 1995;46:60715.
  • 6
    Walsh PC. The natural history of localized prostate cancer: a guide to therapy. In: WalshPC, RetikAB, VaughnED, WenAJ, eds. Campbell's Urology. Philadelphia, PA: W.B. Saunders; 1998:253944.
  • 7
    Hahn DL, Roberts RG. Screening for asymptomatic prostate cancer: truth in advertising. J Fam Pract. 1993;37:4326.
  • 8
    Litwin MS, Hays RD, Fink A., et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:12935.
  • 9
    Andriole GL, Smith DS, Rao G, Goodnough L, Catalona WJ. Early complications of contemporary anatomical radical retropubic prostatectomy. Urology. 1994;152(5 Pt 2):185860.
  • 10
    Fowler FJ, Roman A, Barry MJ, Wasson J, Lu-Yao G, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare experience: 1988-1990. Urology. 1993;42:6229.
  • 11
    Garnick MB, Fair WR. Prostate cancer: emerging concepts. Part I. Ann Intern Med. 1996;125:11825.
  • 12
    Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:26508.
  • 13
    Schroder FH. Screening, early detection, and treatment of prostate cancer: a European view. Urology. 1995;46:6270.
  • 14
    Graverson PH, Nielsen KT, Gasser TC, Corle DK, Madsen PO. Radical prostatectomy versus expectant primary treatment in stages I and II prostatic cancer. A fifteen year follow-up. Urology. 1990;36:4938.
  • 15
    Middleton RG, Thompson IM, Austenfeld MS, et al. Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. J Urol. 1995;154:21448.
  • 16
    Saltus R. For prostate cancer there's no magic bullet. Boston Globe. January 12, 1998:C1.
  • 17
    Schapira MM, Nattinger AB, Katz DA, Lawrence W. Information seeking and satisfaction with treatment decision in patients with clinically localized prostate cancer. Med Decis Making. 1997; 17(suppl):544. Abstract.
  • 18
    Fowler FJ, Bin L, Collins MM, et al. Prostate cancer screening and beliefs about treatment efficacy: a national survey of primary care physicians and urologists. Am J Med. 1998;104:52632.
  • 19
    Feinstein AR. Clinimetrics. New Haven: Yale University Press; 1987.
  • 20
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:37383.
  • 21
    D'amico AV, Coleman CN. Role of interstitial radiotherapy in the management of clinically organ-confined prostate cancer: the jury is still out. J Clin Oncol. 1996;14:30415.
  • 22
    Slovic P. Perception of risk. Science. 1987;236:2805.
  • 23
    Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med. 1997;12:299305.
  • 24
    Johansson JE. Watchful waiting for early stage prostate cancer. Urology. 1994;43:13842.
  • 25
    Sandhu SS, Kaisary AV. Localised carcinoma of the prostate: a paradigm of uncertainty. Postgrad Med J. 1996;73:6916.
  • 26
    Chodak GW. The role of watchful waiting in the management of localized prostate cancer. J Urol. 1994;152:17668.
  • 27
    Steinberg GD, Bales GT, Brendler CB. An analysis of watchful waiting for clinically localized prostate cancer. J Urol. 1998; 159:14316.